找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Competition Law and Policy in the Japanese Pharmaceutical Sector; Akira Negishi,Masako Wakui,Naoko Mariyama Book 2022 The Editor(s) (if ap

[復(fù)制鏈接]
查看: 37450|回復(fù): 52
樓主
發(fā)表于 2025-3-21 17:34:19 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書(shū)目名稱(chēng)Competition Law and Policy in the Japanese Pharmaceutical Sector
編輯Akira Negishi,Masako Wakui,Naoko Mariyama
視頻videohttp://file.papertrans.cn/232/231141/231141.mp4
概述Provides a comprehensive guide to the Japanese pharmaceutical industry, focusing on competition law and policy.Examines the Japanese pharmaceutical sector, including competition, intellectual property
叢書(shū)名稱(chēng)Kobe University Monograph Series in Social Science Research
圖書(shū)封面Titlebook: Competition Law and Policy in the Japanese Pharmaceutical Sector;  Akira Negishi,Masako Wakui,Naoko Mariyama Book 2022 The Editor(s) (if ap
描述.This is the first book published that focuses on competition law and policy in the Japanese pharmaceutical sector. It consists of chapters written and edited by academics who research the industry from various perspectives, including economics, competition law, pharmaceutical regulations, and intellectual property law. ..Competition policies involving pharmaceutical products attract attention from academics and policymakers worldwide. The pharmaceutical industry is regulated by drug laws that vary from country to country and are affected by differing practices and industrial structures. The book begins by examining drug regulations and trade practices in the industry that are peculiar to Japan and its healthcare system. It then presents the Japanese Antimonopoly Act and cases involving it, and discussions of current competition law issues in the Japanese pharmaceutical industry. The book also discusses innovation and intellectual property and economic analyses of pharmaceutical regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States...Japan is one of the biggest pharmaceutical markets in
出版日期Book 2022
關(guān)鍵詞Antitrust law; Competition law; Pharmaceutical regulations; Antimonopoly; Intellectual property; Patent; M
版次1
doihttps://doi.org/10.1007/978-981-16-7814-1
isbn_softcover978-981-16-7816-5
isbn_ebook978-981-16-7814-1Series ISSN 2524-504X Series E-ISSN 2524-5058
issn_series 2524-504X
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapor
The information of publication is updating

書(shū)目名稱(chēng)Competition Law and Policy in the Japanese Pharmaceutical Sector影響因子(影響力)




書(shū)目名稱(chēng)Competition Law and Policy in the Japanese Pharmaceutical Sector影響因子(影響力)學(xué)科排名




書(shū)目名稱(chēng)Competition Law and Policy in the Japanese Pharmaceutical Sector網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱(chēng)Competition Law and Policy in the Japanese Pharmaceutical Sector網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱(chēng)Competition Law and Policy in the Japanese Pharmaceutical Sector被引頻次




書(shū)目名稱(chēng)Competition Law and Policy in the Japanese Pharmaceutical Sector被引頻次學(xué)科排名




書(shū)目名稱(chēng)Competition Law and Policy in the Japanese Pharmaceutical Sector年度引用




書(shū)目名稱(chēng)Competition Law and Policy in the Japanese Pharmaceutical Sector年度引用學(xué)科排名




書(shū)目名稱(chēng)Competition Law and Policy in the Japanese Pharmaceutical Sector讀者反饋




書(shū)目名稱(chēng)Competition Law and Policy in the Japanese Pharmaceutical Sector讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

1票 100.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 21:57:07 | 只看該作者
板凳
發(fā)表于 2025-3-22 03:16:31 | 只看該作者
Competition and Cooperation: Building a Sustainable Healthcare Delivery System in a Society with a Dompetition policy. It then reviews the challenges the system faces. The chapter concludes by discussing the issues to be considered further when creating a sustainable healthcare delivery system and enacting competition policies.
地板
發(fā)表于 2025-3-22 07:00:39 | 只看該作者
Drug Regulation in Japan held liable arises. A remedial system for health damage caused by the proper use of medicinal products also exists. Although remedies are not limited to damage caused by unknown side effects, a certain set of requirements, different from that for civil liability, must be met to for the plaintiff to
5#
發(fā)表于 2025-3-22 09:42:08 | 只看該作者
6#
發(fā)表于 2025-3-22 14:05:04 | 只看該作者
7#
發(fā)表于 2025-3-22 19:45:32 | 只看該作者
8#
發(fā)表于 2025-3-22 23:07:28 | 只看該作者
9#
發(fā)表于 2025-3-23 01:47:01 | 只看該作者
10#
發(fā)表于 2025-3-23 06:11:22 | 只看該作者
2524-504X cal regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States...Japan is one of the biggest pharmaceutical markets in978-981-16-7816-5978-981-16-7814-1Series ISSN 2524-504X Series E-ISSN 2524-5058
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 14:48
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
鄄城县| 安庆市| 泰兴市| 河东区| 山丹县| 赤水市| 文昌市| 临泽县| 庄河市| 同德县| 鞍山市| 呈贡县| 朝阳市| 鲁甸县| 大同县| 上饶市| 武功县| 青龙| 喀什市| 乐亭县| 成都市| 崇左市| 江永县| 湖口县| 嘉定区| 龙井市| 敦化市| 搜索| 定襄县| 黑山县| 黔东| 宜川县| 海门市| 江口县| 韶山市| 高平市| 洞口县| 桐柏县| 阜新市| 贵港市| 交城县|